80 results
8-K
EX-99.1
ZVRA
Zevra Therapeutics Inc
8 May 24
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
7:54am
statements regarding the potential benefits of our debt facility, our cash balance, our corporate governance objectives, potential revenues from our
DEFA14A
ZVRA
Zevra Therapeutics Inc
29 Apr 24
Additional proxy soliciting materials
7:49am
point of value creation.
We’re Committed to Governance Best Practices
From the beginning of 2023 through today, the composition of our Board … .
The newly composed Board immediately moved into action by affirming its commitment to employing governance best practices for a company of our size and stage
424B3
ous6w
10 Oct 23
Prospectus supplement
5:07pm
S-4/A
22e7m3cc zkdor
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm
S-4
26yrb9ckrbmhuz6pz39
28 Sep 23
Registration of securities issued in business combination transactions
9:25pm
425
ozdvlg
31 Aug 23
Business combination disclosure
8:03am
8-K
EX-2.1
khjg9pflk1uyq1jk
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
424B3
btciqgaz1ma6wfl0 3i
10 Nov 21
Prospectus supplement
5:19pm
424B3
ti5496 fy8
19 Oct 21
Prospectus supplement
9:27am